IDENTIFIKASI ADVERSE DRUG REACTION PENGGUNAAN OBAT ANTI TUBERKULOSIS PARU DI UPTD PUSKESMAS KROYA I PERIODE JANUARI 2019 – DESEMBER 2020



Tatang Tajudin(1*), Denih Agus Setia Permana(2), Umi Ulfah(3),

(1) Universitas Al-Irsyad Cilacap
(2) Universitas Al-Irsyad Cilacap
(3) Universitas Al-Irsyad Cilacap
(*) Corresponding Author

Abstract


Adverse Adverse Drug Reaction (ADR) events are quite common, especially in TB patients, it is important for us to monitor ADR to ensure safety during treatment and improve patient quality of life considering the many types of drugs used and the long duration of treatment. The purpose of this study was to determine the identification of Adverse Drug Reactions from the Use of Anti Pulmonary Tuberculosis Drugs in the UPTD of the Kroya 1 Health Center for the period January 2019 - December 2020. This study used an observational method with a sample of 74 patients. The data in this study were obtained from medical record data according to the inclusion and exclusion criteria. The results showed that patients with pulmonary TB at the UPTD Kroya Health Center 1 Period January 2019 - December 2020 with the highest number of patients, namely the adult category or in the age range of 20-60 years as many as 52 patients (70.3%), male and female. male as many as 40 patients (54.1%), in 2019 the intensive stage was (32.4%), the advanced stage (13.5%) while in 2020 the intensive stage was (33.8%) and the advanced stage (20.3%) ). From this study, the results showed the number of patients with ADR in the form of nausea as many as 31 patients (39.2%), no appetite as many as 8 patients (10.1%), itching as many as 13 patients (16.5%), tingling in 10 patients ( 12,7%), joint pain in 7 patients (8,9%), and abdominal pain in 5 patients (6,3%) and 5 patients did not experience ADR (6.3%). There is a significant relationship between the stage of treatment with Adverse Drug Reaction with a value of 0.013. The conclusion was that an adverse drug reaction was identified on the use of anti-pulmonary tuberculosis drugs at the UPTD of the Kroya 1 Health Center for the 2019-2020 period.


Full Text:

PDF

References


Departemen Kesehatan Republik Indonesia, 2014,PedomanPenerapan Formularium Nasional. Direktur Jendral Bina Kefarmasiandan Alat Kesehatan.

Departemen Kesehatan RI, 2008,Profil Kesehatan Indonesia 2008, Departemen Kesehatan Republik Indonesia.

Depkes, 2011,Pedoman Penanggulangan Tuberkulosis, Depkes RI.

Dotulong, J. F. J., Sapulete, M. R., dan Kandou, G. D., 2015, Hubungan faktor risiko umur, jenis kelamin dan kepadatan hunian dengan kejadian penyakit tb paru di desa wori kecamatan wori,Jurnal Kedokteran Komunitas Dan Tropik, III, 57–65.

Emma Novita, dan Z. I., 2017, Studi Karakteristik Pasien Tuberkulosis di Puskesmas Seberang Ulu 1 Palembang,Unnes Journal of Public Health, 6(4), 218–224.

Harbanu H Mariyono, K. S., 2008, Adverse Drug Reaction,J Peny Dalam, Volume 9 N, 164–172.

Kemenkes RI., 2014,Buku Pedoman Nasional Pengendalian Tuberkulosis (T. Novita D. and V. Siagian (ed.), Kementrian Kesehatan RI.

Laily, D. W., Rombot, D. V, Lampus, B. S., dan Paru, T., 2015, Karakteristik pasien tuberkulosis paru di puskesmas tuminting manado,Jurnal Kedokteran Komunitas Dan Tropik, 3, 1–5.

Lamria Pangaribuan, Kristina, Dian Perwitasari, Teti Tejayanti, D. B. L., 2020, Faktor-faktor Yang Mempengaruhi Kejadian Tuberkulosis Pada Umur 15 Tahun Ke Atas Di Indonesia ( Analisis Data Survei Prevalensi Tuberkulosis ( SPTB ) Di Indonesia 2013-2014 ),Buletin Penelitian Sistem Kesehatan, 23.

Lucia Vita Inandha Dewi, Lukman Hakim, Sismindari, Ngatidjan, S. P. P., 2019, Gambaran Reaksi Obat Yang Tidak Dikehendaki pada Pengobatan Tuberkulosis di Puskesmas Kabupaten “X” Yogyakarta dan Hubungannya dengan Kepatuhan Minum Obat. Majalah Farmasetika, 4(Suppl 1), 132–136.

Nurhikma, E., Bina, P., Kendari, H., dan Farmasi, P. D., 2018, Efek Samping Obat Anti Tuberkulosis (OAT) Dan Penanganannya Pada Pasien Tuberkulosis ( TB ),Jurnal Ilmiah Manuntung, 4(1), 67–73.

Nurkumalasari, Dian Wahyni, N. N., 2016, Hubungan Karakteristik Penderita Tuberkulosis Paru Dengan Hasil Pemeriksaan Dahak Di Kabupaten Ogan Ilir,Jurnal Keperawatan Sriwijaya, 3(2355), 51–58.

Pratiwi, E. P., Rohmawaty, E., dan Kulsum, I. D., 2018, Efek Samping Obat Antituberkulosis Kategori I dan II Pasien Tuberkolosis Paru Dewasa di Rumah Sakit Hasan Sadikin, Jurnal Farmasi Klinik Indonesia, 7(4), 1–8.

Sari, I. D., Yuniar, Y., dan Syaripuddin, M., 2014, Studi Monitoring Efek Samping Obat Antituberkulosis FDC Kategori 1 di Provinsi Banten dan Provinsi Jawa Barat,Media Litbangkes, 24(1), 28–35.

Vitarani Dwi Ananda Ningrum, Arnia Megasari, S. H., 2010, Hepatotoksisitas pada Pengobatan Tuberkulosis di RSUD Tangerang-Indonesia,Jurnal Ilmiah Farmasi, Volume 7 N.


Article Metrics

Abstract Views : 427 | PDF Views : 270

Refbacks

  • There are currently no refbacks.